Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of beriberi heart failure in a chronic hemodialyzed patient is described. The etiology and the diagnostical criteria are discussed. The possibility of this complication in chronic hemodialyzed patients is considered.
Nephron 1975
PMID:A possible case of beriberi heart failure in a chronic hemodialyzed patient. 12 21

The treatment of 34 patients with secondary aldosteronism with a new oral and parenteral preparation (Osyrol) is reported. On the strength of the clinical results with remissions of signs of heart failure and increase in the volume of urine, reduction of body weight and raising of serum potassium, the efficacy of the preparation with good general and local tolerance is described.
 ...
PMID:[Clinical experience in the use of Osyrol 100 and Osyrol for injection (author's transl)]. 81 Jun 73

Serial measurements of vital capacity (VC) were performed on nine patients on chronic haemodialysis. In six patients the VC remained stable, they were all adequately dialysed and working full-time. Reduction of dialysis time in one of these patients brought about a gradual onset of left heart failure which was preceeded by a decline of VC. In the three remaining patients a decrease of VC preceeded the onset of heart failure, and a rise of VC values signified improvement of cardiac performance. Serial recordings of VC are recommended as a useful objective guide to evaluation and treatment of patients on haemodialysis.
Nephron 1977
PMID:Serial measurement of vital capacity in patients on chronic haemodialysis. 89 62

The authors report on the myocardiopathy of seven patients with end-stage renal disease, characterized by fever, in four patients; tachycardia, gallop rhythm, pericardial rub, in most of patients; signs and symptoms of cardiac failure and increased cardiac area and alterations of the EKG in all patients. Good remission of the symptoms ws achieved in two patients by hemodialysis and by successful renal transplantation in the others. The likely etiologic factors of the syndrome are discussed.
Nephron 1975
PMID:Uremic myocardiopathy. 109 61

A 60-year-old uremic patient treated with hemodialysis for 13 years developed acute hypotension during hemodialysis and overt heart failure subsequently in a period of relatively mild hypocalcemia after parathyroidectomy. Blood pressure during hemodialysis was maintained by continuous calcium infusion alone. Cardiomegaly was improved by normalization of serum calcium. The cardiac complication is considered to be exacerbation of the underlying myocardial dysfunction by the acute decline of serum calcium which might be a feature of the 'hungry bone' syndrome. Latent myocardial dysfunction might be exacerbated by only mild hypocalcemia after parathyroidectomy in long-term hemodialysis patients.
Nephron 1992
PMID:Exacerbation of latent heart failure by mild hypocalcemia after parathyroidectomy in a long-term hemodialysis patient. 158 26

The article reports the efficacy and tolerability of a new slow-release formulation of furosemide (Lasix Retard) given to an elderly (mean: 72 years, range 48-92) population (n = 115, 77 females) suffering from hypertension or heart failure. In 34 of 52 patients with heart failure the clinical condition improved. Lasix Retard reduced blood pressure significantly from 187/99 to 166/93 after one year on 30 mg/day (n = 19). It was found that Lasix Retard replaces thiazide diuretics without causing any significant change in blood pressure. There were no significant changes in metabolic indicators (S-potassium, S-urate, S-glucose). Side effects were in the same range as reported for thiazide diuretics. There were 33 (29%) drop-outs.
 ...
PMID:[Furosemide capsules in the treatment of hypertension or heart failure in the elderly in general practice]. 233 10

We analyzed the effect of enalapril (0.1 mg/kg p.o. twice daily) on plasma electrolytes, urea, and creatinine in low cardiac output failure. In 14 male dogs implanted with chronic instrumentation, tachycardia was induced by ventricular pacing (265 impulses/min., 10-14 days). In 7 untreated dogs, pacing progressively lowered aortic flow by 44% and induced hyponatremia and elevations of plasma urea, creatinine, and potassium. Treatment with enalapril (n = 7) during pacing reduced the decrease in aortic flow by 33% and prevented changes in plasma urea, potassium, and sodium. We conclude that this is due to enalapril-induced retardation of heart failure progression.
Nephron 1990
PMID:Converting enzyme inhibition by enalapril in experimental heart failure. 234 93

This paper discusses the possible pathogenesis of the cerebral atrophy (CA) observed in a large percentage of uraemic patients, taking the form of prevalently cortical damage (cortical atrophy) and/or subcortical enlargement of ventricular cavities (subcortical atrophy). This central nervous system pathology seems to share very little either with the better known 'dialysis encephalopathy' or with the 'acute encephalopathy syndrome', even though sporadic cases of both these forms have shown concomitant CA. Histopathologically it offers the picture of loss of neurons and nerve fibres and can thus be compared with uraemic peripheral nervous system damage. CA is unquestionably important because of its implications in terms of impairment of superior cortical functions, just as in CA of non-uraemic aetiology. A first aetiopathogenic hypothesis might include endogenous uraemic intoxication to the nerve tissue, believed responsible for peripheral uraemic neuropathy, but other possibilities merit consideration: vascular calcification secondary to hyperparathyroidism, blood lipid disorders, and systemic hypertension--factors that contribute to impairing the brain vasculature, with cascade effects on brain tissue oxygenation, neuronal metabolism, and energy exchanges. Tissue oxygenation is already jeopardized in the uraemic patient by the concomitant chronic anaemia and by cardiac insufficiency in cases with hypertensive heart disease. In dialysis patients with volume-dependent hypertension the brain may be further damaged by abrupt pressure changes produced by dialytic ultrafiltration; these constitute a severe challenge to cerebral blood flow autoregulation. Cyclic variations of brain tissue hydration connected with regular dialysis treatment may have adverse effects on neurotransmitter functions, particularly those mediated by neuropeptidergic systems. Chronic intoxication may result from oral Al(OH)3 of phosphorus-chelating agents: in animal studies and clinical observations in non-uraemic populations the neurotoxic potential of Al is indicated by a significant correlation between histological neuronal damage, impaired function, and Al concentration in brain tissues. In addition, a concausal role of malnutrition in central nervous system damage in the uraemic patient cannot be overlooked, since malnutrition is known to give rise to functional and structural alterations in non-uraemic human pathology. In the light of these clinical observations and experimental findings, it would appear that the prevention of CA in uraemia is today feasible.
Nephron 1988
PMID:Pathogenesis of cerebral atrophy in uraemia. State of the art. 328 91

2 cases of acute renal failure associated with diclofenac therapy are reported. In the 1st case no other risk factors but diclofenac administration were identified. Renal biopsy showed patchy interstitial infiltration of mononuclear cells and polymorphonuclear leukocytes. In the 2nd case preexisting nephropathy and heart failure were underlying illnesses. In both cases renal function returned to the basal values after stopping the drug.
Nephron 1985
PMID:Diclofenac-associated acute renal failure. Report of 2 cases. 402 22

Nineteen ambulant patients in cardiac insufficiency stages III to IV, eleven of them concomitantly presenting hypertension, were treated with Osyrol 50-Lasix for a period of three months. With a maintenance dose consisting on average of one capsule Osyrol 50-Lasix daily, effective and reliable elimination of edema and adequate recompensation of the heart was achieved by way of reduction of the body weight, decrease in ankle circumference, congestion of the liver and improvement of dyspnoea. In the eleven patients with hypertension grade I, the systolic and diastolic blood pressure was normalized under Osyrol 50-Lasix medication, whilst the blood pressure values of normotensive patients were practically unchanged. The serum potassium values at the beginning of the study were 4.29 mmol/l on average and increased moderately to 4.83 mmol/l after three months' therapy. Compared to pre-trial controls the serum values of creatinine and uric acid showed no changes attributable to the drug after three months' therapy with Osryol 50-Lasix. No significant change of the fasting blood glucose values was ascertained either in the nondiabetic or in the diabetic patients. Based on the clinical and laboratory-chemical parameters the success of therapy was considered to be good in 18 patients and satisfactory in one case. Tolerability was also considered to be good in 18 cases. Transient side effects were observed in two patients. Hypotension was diagnosed in one case after four weeks' treatment and in a further patient an increased serum potassium level was found. After reducing the dose the values reverted to normal in both cases.
 ...
PMID:[Long term experiences with a solid spironolactone-furosemide combination in heart insufficiency and hypertension]. 680 28


1 2 3 4 Next >>